Posted by Michael Wonder on 29 Jul 2019
Roche receives CHMP positive opinion for new Tecentriq-based combination therapy as an initial treatment for most common form of advanced lung cancer
26 July 2019 - Decision based on data showing that the Tecentriq plus chemotherapy combination demonstrated a significant overall survival and progression-free survival benefit in the first-line treatment of people with advanced, non-squamous non-small cell lung cancer.
Roche today announced that the EMA's CHMP has adopted a positive opinion for Tecentriq (atezolizumab) in combination with chemotherapy (carboplatin and Abraxane [albumin-bound paclitaxel; nab-paclitaxel]), for the initial (first-line) treatment of adults with metastatic non-squamous non-small cell lung cancer (NSCLC) who do not have EGFR mutant or ALK-positive NSCLC.
This decision is based on results from the Phase III IMpower130 study, which demonstrated that the Tecentriq combination therapy helped people live significantly longer, compared with chemotherapy alone (median overall survival [OS]=18.6 versus 13.9 months; hazard ratio [HR]=0.79; 95% CI: 0.64–0.98; p=0.033) in the intention-to-treat population.
